
|Videos|November 15, 2013
Hepatitis C: Patient Warehousing
Aimee Tharaldson of Express Scripts explains why some hepatitis C patients who do not have signs of active disease may want to wait to receive treatment until later this year and early next year, when the FDA is expected to approve sofosbuvir and simeprevir for the treatment of this condition.
Advertisement
Aimee Tharaldson of Express Scripts explains why some hepatitis C patients who do not have signs of active disease may want to wait to receive treatment until later this year and early next year, when the FDA is expected to approve sofosbuvir and simeprevir for the treatment of this condition.
This video was shot at the 2013 Academy of Managed Care Pharmacy Nexus meeting in San Antonio, Texas.
Advertisement
Advertisement
Advertisement
Trending on Pharmacy Times
1
Beyond Cost Avoidance: Advancing Unit-Level Pharmaceutical Economics in Health Systems
2
Pharmacist Care Gets BP Patients to Goal Faster, Safer
3
Higher Pulmonary Microplastic Burden Observed in Patients With Lung Cancer
4
FDA Approves Apitegromab-mstn, First Muscle-Targeted SMA Therapy
5



































































































